Emerson (NYSE:EMR) today issued the following statement regarding its all-cash proposal to acquire National Instruments ("NI") (NASDAQ:NATI) for $53 per share.
Emerson's objective with publicly disclosing
Gainers
Celyad Oncology SA (NASDAQ: CYAD) jumped 187% to $2.30 after gaining 21% on Friday. Celyad Oncology, last month, decided to discontinue the development of its remaining clinical program CYAD-211.
National Instruments Corp’s (NASDAQ:NATI) board evaluates strategic options in consultation with its financial and legal advisors. The comprehensive review will…